VIP (Vasoactive Intestinal Peptide) is a 28-amino acid neuropeptide with potent vasodilatory, bronchodilatory, and immunomodulatory properties. It is studied for conditions including pulmonary arterial hypertension, inflammatory bowel disease, and autoimmune conditions. This review summarizes the adverse effects observed in available research.
Research Use Only: This information is for educational and research purposes only. VIP is not FDA-approved for human use. Consult a qualified healthcare professional before any use.
VIP exerts its effects through VPAC1 and VPAC2 receptors, activating adenylate cyclase and increasing intracellular cAMP. This leads to smooth muscle relaxation, vasodilation, bronchodilation, and modulation of immune cell function including T regulatory cell induction.
Facial flushing is the most commonly reported adverse effect of VIP administration, consistent with its potent vasodilatory mechanism. It is typically transient and dose-dependent.
Blood pressure reduction is an expected pharmacological effect of VIP given its vasodilatory properties. Research subjects with baseline hypotension should be monitored carefully.
Compensatory tachycardia in response to vasodilation and blood pressure reduction has been reported in research subjects.
Mild redness, swelling, or discomfort at the injection site have been reported in research subjects receiving subcutaneous or intravenous administration.
Mild nausea has been reported in some research subjects, particularly at higher doses.
Gastrointestinal effects including diarrhea have been reported, consistent with VIP's role in intestinal motility regulation.
Headaches have been reported in some research subjects, potentially related to vasodilatory effects.
VIP has potent vasodilatory effects that can cause clinically significant hypotension and tachycardia, particularly at higher doses or with intravenous administration. Research subjects with cardiovascular conditions, hypotension, or those taking antihypertensive medications require careful monitoring. It is not FDA-approved for human use and should only be used in legitimate research settings.
Yes. VIP has potent vasodilatory effects and can cause clinically significant hypotension, particularly at higher doses or with intravenous administration. Research subjects with cardiovascular conditions require careful monitoring.
VIP can be used safely in research settings with appropriate monitoring for cardiovascular effects. It is not FDA-approved for human use and should only be used in legitimate research settings.
VIP's vasodilatory effects may be additive with antihypertensive medications, potentially causing excessive blood pressure reduction. Research subjects on antihypertensives require careful monitoring.
Yes. VIP has immunomodulatory effects including induction of T regulatory cells and suppression of pro-inflammatory cytokines. These effects are part of its research interest for autoimmune conditions.
Purgo Labs provides research-grade VIP with third-party HPLC and mass spectrometry verification from accredited US laboratories. Every batch ships with a full Certificate of Analysis.
Shop VIP at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.